Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Cortesi

Showing results (151-160 of 174) with videos related to

Pageof 18
Sort By:
Targeted Oncology|August 29, 2020
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Cancer Immunology, Immunotherapy : CII|March 3, 2023
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approachAndrea Botticelli, Alessio Cirillo, Giulia Pomati, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2019
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancerLucio Crinò, Giuseppe Bronte, Paolo Bidoli, et al.
Critical Reviews in Oncology/Hematology|December 5, 2017
Management of salivary gland malignant tumor: the Policlinico Umberto I, "Sapienza" University of Rome Head and Neck Unit clinical recommendationsFrancesca De Felice, Marco de Vincentiis, Valentino Valentini, et al.
British Journal of Cancer|May 20, 2020
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti, et al.
Critical Reviews in Oncology/Hematology|October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trialsDaniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 26, 2021
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without <sup>223</sup>RaOrazio Caffo, Viviana Frantellizzi, Fabio Monari, et al.
Cancers|January 30, 2019
A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal CancerCarlo Capalbo, Francesca Belardinilli, Domenico Raimondo, et al.
Journal of the National Cancer Institute|April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialStefano Cascinu, Roberto Labianca, Carlo Barone, et al.
NPJ Breast Cancer|July 17, 2024
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY studySimone Scagnoli, Simona Pisegna, Angela Toss, et al.
Pageof 18

Showing results (151-160 of 174) with videos related to

Sort By:
Pageof 18
Targeted Oncology|August 29, 2020
Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional AnalysisRoberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, et al.
Cancer Immunology, Immunotherapy : CII|March 3, 2023
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approachAndrea Botticelli, Alessio Cirillo, Giulia Pomati, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2019
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancerLucio Crinò, Giuseppe Bronte, Paolo Bidoli, et al.
Critical Reviews in Oncology/Hematology|December 5, 2017
Management of salivary gland malignant tumor: the Policlinico Umberto I, "Sapienza" University of Rome Head and Neck Unit clinical recommendationsFrancesca De Felice, Marco de Vincentiis, Valentino Valentini, et al.
British Journal of Cancer|May 20, 2020
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti, et al.
Critical Reviews in Oncology/Hematology|October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trialsDaniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 26, 2021
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without <sup>223</sup>RaOrazio Caffo, Viviana Frantellizzi, Fabio Monari, et al.
Cancers|January 30, 2019
A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal CancerCarlo Capalbo, Francesca Belardinilli, Domenico Raimondo, et al.
Journal of the National Cancer Institute|April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialStefano Cascinu, Roberto Labianca, Carlo Barone, et al.
NPJ Breast Cancer|July 17, 2024
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY studySimone Scagnoli, Simona Pisegna, Angela Toss, et al.
Pageof 18